Last $104.07 USD
Change Today +1.31 / 1.27%
Volume 10.2M
JNJ On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
Sao Paulo
Bogota
As of 8:04 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Hires Jorge Mesquita as Worldwide Chairman of Its Consumer Companies, Effective December 15, 2014

Former Procter & Gamble group president Jorge Mesquita has been hired by P&G competitor Johnson & Johnson as worldwide chairman of its consumer companies. Mesquita, 53, will join the company on Dec. 15. J&J's brands include Listerine Whitening strips and Neutrogena soap and shampoo. P&G's brands include Crest 3D Whitening Strips, Ivory soap and Head & Shoulders shampoo. Mesquita joined P&G in 1984 and became group president for new business creation & innovation in 2012. As group president for global fabric care from 2007-11, Mesquita oversaw the introduction of Tide Pods. He left the Cincinnati-based company in June 2013. In his role with J&J, Mesquita will lead the Consumer Group Operating Committee and serve on the corporation's Management Committee. He will be responsible for accelerating the growth of brands such as Listerine, Neutrogena, Aveeno and Tylenol. Mesquita will report to Sandi Peterson, J&J's group worldwide chair.

J&J Reportedly Hires Goldman To Explore Sale Of Splenda

Johnson & Johnson (NYSE:JNJ) (J&J) has hired Goldman Sachs to explore a sale of its artificial sweetener brand Splenda, sources familiar with the matter, said. The process is at an early stage, with prospective buyers signing non-disclosure agreements, one of the sources said speaking on condition of anonymity because the matter is private.

Johnson & Johnson Provides Update on Claim Alleging Defects in Fentanyl Patch Caused Patient's Death

The U.S. District Court for the Northern District of Oklahoma held the applicable statute of limitations barred an estate's claims against drug manufacturers stemming from the death of a patient due to defects in the manufacturers' fentanyl patch. Rose Ballard and Alana Newton, individually and as co-personal representatives of the estate of Jimmy Ballard, alleged Jimmy Ballard died on Nov. 3, 2005, due to defects in a fentanyl patch. The patch was manufactured, sold, distributed and placed in the stream of commerce by Johnson & Johnson, a/k/a Johnson & Johnson Inc., a/k/a Johnson & Johnson Co., Janssen Pharmaceutical Productions L.P., ALZA Corp., Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan). A fentanyl patch was found on the body at the time of death. Rose and Newton brought an action against Johnson & Johnson, Janssen, ALZA and/or Mylan asserting claims for strict liability, negligence, fraud, wrongful death and breach of warranty. Mylan moved to dismiss alleging the claims were barred by applicable statute of limitations. The district court granted Mylan's motion. The plaintiffs' claims for strict liability, negligence, fraud and wrongful death were subject to two-year statutes of limitation. Mylan's statute of limitations defense was established on the face of the April 25, 2014, petition, which alleged decedent was found dead in his home on Nov. 3, 2005, a fentanyl patch was found on his body, and the medical examiner determined the cause of death was 'toxic effects of fentanyl'. Therefore, the plaintiffs' claims for strict liability, negligence, fraud and wrongful death were time-barred. The district court noted the plaintiffs' claim for breach of warranty was subject to a five-year statute of limitations, and the statute of limitations for breach of warranty accrued upon 'delivery' of the goods, regardless of the aggrieved party's lack of knowledge of the breach. The petition alleged decedent filled the prescription for the fentanyl patch on Nov. 1, 2005. Therefore, the statute of limitations on the plaintiffs' breach of warranty claim ran on Nov. 1, 2010. Accordingly, the breach of warranty claim was time barred.

Wrongful Death Suit Alleges Johnson & Johnson Pharmaceuticals and Bayer Corp for Woman's Death

The estate of a woman who died in March 2014 filed a lawsuit alleging that Johnson & Johnson Pharmaceuticals is responsible for her death. According to the lawsuit, Johnson & Johnson-through its Janssen Pharmaceuticals subsidiary-marketed the drug Xarelto to be used as a blood thinner. The lawsuit claims Emily Pigg took Xarelto from October 2013 to December 2013 and subsequently suffered to life-threatening bleeds in late 2013. The lawsuit alleges that as a result of those injuries, Pigg died in March. The lawsuit seeks equitable relief, monetary restitution, compensatory damages and punitive damages. The lawsuit also names Bayer Corp. and related entitles as defendants.

Johnson & Johnson Presents at Emerging Medical Technologies Summit, Nov-12-2014 09:45 AM

Johnson & Johnson Presents at Emerging Medical Technologies Summit, Nov-12-2014 09:45 AM. Venue: Sofitel Hotel San Francisco, 223 Twin Dolphin Dr., Redwood City, CA 94065, United States. Speakers: Susan Morano, Vice President of Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $104.07 USD +1.31

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $24.66 USD +0.17
Intel Corp $36.24 USD +0.68
International Business Machines Corp $151.93 USD +0.52
Pfizer Inc $31.12 USD +0.45
Procter & Gamble Co/The $90.70 USD +1.34
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 17.0x
Price/Sales 3.9x
Price/Book 3.8x
Price/Cash Flow 16.6x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.